Browse studies

Find your next paid study

26,715 recruiting studies available now

A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS Less Than or Equal to 25 (RxFINE-Low)

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of…

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07391774

Phase 1

An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy…

Multiple Myeloma

Estimated

~$10 – $8,750

Genentech, Inc.NCT04910568

Phase 3

A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Plaque Psoriasis

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07116967

Phase 2

A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma - SPARCC

The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants wit…

Metastatic Renal Cell CarcinomaMetastatic Renal CancerRenal Cell Carcinoma+3 more

Estimated

~$10 – $7,500

Stephanie BergNCT07123090

Observational

Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Loss of skeletal muscle mass or sarcopenia is the most common and potentially reversible complication in cirrhosis that increases morbidity and mortality befor…

Cirrhosis, Liver

Estimated

~$10 – $6,250

The Cleveland ClinicNCT03208868

Observational

Investigation on the Cortical Communication (CortiCom) System

The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an ex…

TetraplegiaLocked-in SyndromeBrainstem Stroke+1 more

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT03567213

Phase 2

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa

This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with mode…

Hidradenitis Suppurativa

Estimated

~$10 – $7,500

SanofiNCT07170917

A Randomized, Investigator-masked, Longitudinal Study Evaluating Long-term Changes in Symptoms and Tear Production of Acoltremon Ophthalmic Solution 0.003% Compared to Control in Subjects With Dry Eye Disease

This is a prospective, longitudinal, single-center study designed to evaluate the long-term changes in symptoms and tear production in subjects with dry eye di…

Dry Eye

Estimated

~$10 – $1,125

The Eye Care InstituteNCT07659626

Phase 3

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading th…

Diffuse Large B-Cell Lymphoma

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06717347

Phase 3

Adjuvant Steroid Outcomes in Idiopathic Subglottic Stenosis

This study will examine the ability of steroid injections into the site of stenosis following surgical dilation to delay the need for repeated surgical dilatio…

Idiopathic Subglottic Stenosis

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07228104

PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department: PERVADE-ED Study

Supraventricular tachycardia (SVT) is a dysrhythmia characterized rapid heart rate, typically with rapid onset. SVT accounts for over 50,000 emergency departme…

Supraventricular Tachycardia (SVT)

Estimated

~$10 – $750

University of IowaNCT07086560

Phase 2

Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)

This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely t…

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05327010